Articles tagged with Drug Therapy
Researchers found that mitochondrial protein CHCHD2 is associated with increased tumor growth, invasion, and resistance to chemotherapy in glioblastoma patients. CHCHD2 interacts with mutated EGFR to increase sensitivity to cytotoxic drugs, highlighting its potential as a therapeutic target.
A team of researchers aims to develop drug therapies by targeting genes that affect metabolism in people with Down syndrome, potentially improving their quality of life. The project will focus on the protein SIM2, which has been linked to breast cancer and metabolic changes in individuals with the condition.
Researchers have discovered new insights into microglia-astrocyte communication and its impact on intracerebral hemorrhage, as well as the testicular toxicity of triptolide. Additionally, a study on epicardial cells has identified key gene markers associated with cardiac regenerative therapy strategies.
Researchers developed a nanotechnology method to deliver medication through the blood-brain barrier, overcoming its selectivity and expanding therapeutic options for glioblastoma treatment. The technique demonstrated improved tumor shrinkage and survival rates in mice, paving the way for further preclinical studies.
Researchers at UCSF found a feedback loop between immune protein IL-31 and nerve cells, which dials back nearby inflammation and promotes skin healing. This discovery could lead to new treatments for conditions like eczema, allergies, and asthma by targeting the nervous system's role in regulating the immune response.
TTUHSC researchers received funding for pilot studies on photothermal tumor therapy, clear cell renal cell carcinoma, and colorectal cancer screening in underserved areas. The grants support the purchase of a cell sorter and address regional health disparities.
Researchers developed a nanocapsule that reduces lactate levels and releases hydrogen peroxide, recruiting and activating immune cells to attack tumors. The approach increased immune cell activity by 2-5-fold, improving cancer immunotherapy success rates.
A study by researchers at the University of California - Riverside found that certain aspects of video game play can stimulate dopamine release and potentially aid in treating Parkinson's disease symptoms. The research suggests a promising new approach for managing the condition.
A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.
Scientists at Temple University's Alzheimer's Center have identified a promising new therapeutic target for Alzheimer's disease: the protein ABCA7. The study found that cholesterol depletion and inflammation suppress ABCA7 levels in human brain cells, potentially contributing to disease onset.
Researchers found tirzepatide equally effective in treating young-onset and late-onset type 2 diabetes, improving HbA1c levels and weight. The drug also showed similar benefits in cardiometabolic markers such as waist circumference and blood pressure.
A new study reveals that esketamine nasal spray is effective in treating treatment-resistant depression, with 27.1% of patients achieving remission after 8 weeks compared to 17.6% on quetiapine XR. Long-term data shows sustained remission rates at 21.7% for esketamine NS and 14.1% for quetiapine XR.
Brazilian researchers screened 160 existing drugs and identified six compounds effective against Toxoplasma gondii. Almitrine, a COPD treatment, showed significant reduction in brain parasite load. Further studies are needed to repurpose these drugs for toxoplasmosis treatment.
Scientists at Johns Hopkins Medicine have identified a protein mutation in CD8+ T cells that can make them more effective against cancer and infections. The mutated T cells were found to be more active when stimulated, persist longer, and expand in great numbers during the initial immune response.
Researchers found that administering precursors of Elovanoids improved neurological deficit in an experimental model of ischemic stroke. The study identified a cascade of gene responses and sheds light on potential new therapeutic avenues for treating ischemic strokes.
Men with metastatic prostate cancer in Sweden experienced an average survival rate increase of six months after dual treatment was introduced from 2016 onwards. This improvement coincides with the gradual rollout of 'dual treatment', combining standard hormone therapy and chemotherapy or androgen receptor blockers.
Researchers at MedUni Vienna discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of P-glycoprotein, opening new possibilities for delaying relapse. This breakthrough could represent a step forward in treating aggressive triple-negative breast cancer, which has limited treatment options and ...
Armida Labs, a UCR-founded pharmaceutical company, has received a $400,000 NIH Small Business Innovation Research grant to develop its breakthrough pancreatic cancer therapy Targefrin. The grant will enable the company to gather industry-standard data for human clinical trials.
A real-world study of over 23,000 adults with type 2 diabetes found that semaglutide significantly improved blood sugar control and weight loss for up to 3 years. The study showed that patients who had never taken a GLP-1 RA or those with higher adherence achieved more pronounced reductions in blood sugar levels and weight loss.
A new study published in Exp. Mol. Med. has identified Thrap3 as a key player in exacerbating non-alcoholic fatty liver disease (NAFLD) by inhibiting AMPK, a crucial regulator of fat metabolism. Inhibiting Thrap3 expression presents a promising avenue for treating NAFLD.
A new drug called vorasidenib has been shown to significantly slow tumor growth and extend the average time until tumor growth in patients with grade 2 IDH-mutant gliomas. This breakthrough could offer a first early treatment option for these cancer patients, potentially improving their quality of life.
A study by UC San Francisco researchers found that patients with acute kidney injury on outpatient dialysis may not need lifelong treatment if they have the potential to recover. The study tracked data from over 1,700 patients and showed that approximately three-quarters of those who recovered kidney function discontinued dialysis with...
A new study published in JAMA Network Open suggests that reattribution of pain to mind or brain processes can lead to significant reductions in chronic back pain intensity. Participants who received pain reprocessing therapy reported being pain-free or nearly so after treatment, compared to those receiving placebo controls.
Researchers have discovered a peptide that stabilizes the normal structure of alpha-synuclein protein, preventing misfolding and toxic clumps. This breakthrough could lead to new therapeutic developments for neurodegenerative diseases like Parkinson's.
Five lung stem cell variants dominate CF lungs, causing inflammation, fibrosis, and mucin secretion. CFTR modulators fail to suppress these inflammatory variants, suggesting they as key targets for new drugs.
A study of 69,000 adults with hepatitis C virus (HCV) infection found no difference in sustained virologic response across alcohol use categories. This suggests that restricting access to direct-acting antiviral therapy based on alcohol use may create unnecessary barriers for patients. The findings challenge HCV elimination goals.
A team of scientists has developed a method to detect active Cullin-RING ligases (CRLs), which are responsible for destroying unwanted proteins in cells. The new technology, called a molecular radar, reveals which CRLs are deployed to address cellular stresses and perform the actions of some anti-cancer drugs.
A significant increase in the need for treatment of eye diseases is expected due to the growing elderly population. The number of patients requiring anti-VEGF medication is projected to rise by 50% over the next five years.
Researchers identified potential therapeutic targets for Alzheimer's disease and other conditions using a new approach combining AI-driven target identification with protein phase separation analysis. The study provides insights into the role of protein phase separation in human disease and its potential as a therapeutic target.
Researchers have identified a specific error in the NOTCH1 gene that causes rare kidney cancer reninoma. The study found that using existing drugs targeting this gene could serve as an alternative treatment for patients where surgery is not recommended.
A promising drug candidate CDNF has been found to prolong the lifespan of ALS patients and alleviate symptoms in rats and mice. The study suggests that CDNF may rescue motoneurons by reducing ER stress response and cell death.
Researchers explore kinase inhibitors as targeted therapies for specific CRC subsets, offering hope for improved treatment options. Key findings suggest that uncovering essential kinases for tumor growth can lead to more effective treatment strategies in metastatic or later-stage CRC patients.
Research found ginger consumption makes neutrophils more resistant to NETosis, a process that contributes to inflammation and autoimmune diseases. Ginger supplementation also boosted chemical levels in neutrophils, inhibiting NETosis in response to disease-relevant stimuli.
A study of 68,000 patients with COVID-19 found that using Paxlovid or Lagevrio significantly reduced mortality and hospitalization rates in those at high risk of progressing to severe COVID-19, regardless of age, race, or virus strain. These medications can be used to treat non-hospitalized patients at high risk of severe disease.
A study published in the Chinese Medical Journal reveals that methotrexate can be an effective treatment for liver cancer with a specific genetic mutation. The drug works by disrupting nucleotide synthesis in cancer cells, making it a promising alternative to current first-line treatments.
A study found sociodemographic-based disparities in COVID-19 therapeutic drug availability, revealing gaps in treatment access. The research highlights the need for targeted interventions to address these disparities.
Researchers found that DPP4 inhibition increased sunitinib efficacy in RCC spheroids and upregulated DPP4 in sunitinib-resistant cells. This suggests potential repurposing of DPP4 inhibitors to target therapy resistance in renal cell carcinoma.
Researchers at Nagoya University developed a unique supramolecule to remove cholesterol from macrophages, stopping the development of non-alcoholic steatohepatitis (NASH) in mice. Cholesterol crystals are also found in human patients, suggesting a potential therapeutic strategy.
A nationwide study found that early treatment with plasma from recovered COVID patients can reduce the risk of developing post-COVID conditions. The research also suggests that elevated cytokine levels, particularly interleukin-6, may contribute to long COVID symptoms.
The American College of Physicians has issued updated rapid, living practice points on treating COVID-19 patients in outpatient settings. The new guidance supports the use of molnupiravir or nirmatrelvir-ritonavir for symptomatic patients with confirmed mild to moderate COVID-19.
Researchers have identified novel therapeutic targets using single-cell and spatially resolved omics, including cannabidiol for colorectal tumors, Cux1 as a potential target for dry skin diseases, and microglia communication for Alzheimer's disease. These studies offer hope for future treatments.
Philip Low, a Purdue University researcher, is working on validating a previously successful malaria treatment by reducing the number of days required for therapy. His goal is to prevent drug-resistant strains from proliferating and save lives in developing countries.
A new Northwestern Medicine study reveals that a dysfunction in the neuron's synapses leads to deficits in dopamine and precedes neurodegeneration in Parkinson's disease. The findings suggest targeting dysfunctional synapses before neurons degenerate may represent a better therapeutic strategy.
A study published by UCI researchers found that N-acetylglucosamine reduced multiple inflammation and neurodegeneration markers in patients with Multiple Sclerosis. The dietary supplement also improved neurological function in 30% of patients, suggesting a potential new treatment for the condition.
Researchers discuss new drugs available for HER2-positive breast cancer patients with brain metastasis, showing improved outcomes and quality of life. The development of targeted therapies has led to better survival rates among these patients.
Preclinical data shows GP-2250's antineoplastic activity in pancreatic tumor cell lines, reducing ATP levels and inhibiting NF-kB. The compound targets aerobic glycolysis, a hallmark of cancer metabolism, providing a potential treatment for various cancers.
A recent study published in PLOS Biology suggests that chemotherapy injury to surrounding non-cancer cells can awaken dormant breast cancer cells, promoting cancer growth and recurrence. The researchers found that the release of specific cell signaling molecules, G-CSF and IL-6, by injured stromal cells drives this process.
A study published in Brain, Behavior, and Immunity found that inflammation-related genes play a significant role in depression. The researchers discovered correlations between immune-related genes, DNA methylation patterns, and brain structure abnormalities in patients with major depressive disorder.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Researchers found that patients' immune systems play a vital role in determining the duration of remission from multiple myeloma. Sustained minimal residual disease (MRD) negativity is associated with prolonged survival, with patients achieving MRD negativity for at least two years remaining free from multiple myeloma 10 years later.
The study validates a comprehensive genomic profiling assay, NeXT Dx, which detects single nucleotide variants, indels, copy number alterations, and gene fusions. The assay demonstrates high analytic sensitivities and specificity, providing personalized recommendations critical to clinical decision-making.
A recent clinical trial led by Professor Holger Thiele found that ECLS does not reduce 30-day mortality after cardiogenic shock, but is associated with more complications. The study involved 420 patients and compared ECLS therapy with standard intensive care unit treatment.
Researchers developed a liver-targeting drug that reversed obesity and lowered cholesterol in obese mice by delivering the drug via nanogel. The treatment, which was administered intraperitoneally, effectively normalized weight and reduced cholesterol levels despite continued high-fat diet consumption.
A new study presented at ESC Congress 2023 found that semaglutide improved heart failure-related symptoms, physical function, and exercise function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. The treatment also resulted in greater weight loss compared to placebo.
Researchers Elzbieta Izbicka and Robert T. Streeper discuss the evolution of cancer drug development, highlighting recent progress and emerging challenges due to environmental factors. They also examine how artificial intelligence may impact future drug development.
A new clinical study found that adjuvant treatment with Mitotane is not necessary for patients with low risk of recurrence if they have a complete R0 resection, low tumour stage and Ki-67 levels below 10%. This approach has shown no significant improvement in relapse rate but is associated with side effects.
A study of 24,000 hospitalized COVID-19 patients found that pulse oximetry led to delayed treatment and higher readmission rates, with racial disparities observed among black patients. The study highlights the importance of accurate oxygen saturation monitoring in preventing these outcomes.
Researchers found that urine levels of adenine are predictive and causative biomarkers of looming progressive kidney failure in patients with diabetes. An oral therapeutic drug showed promise in mice by reducing kidney adenine levels and protecting against diabetic kidney disease.
A team of KAUST researchers has found a critical protein that regulates cell division and proliferation in breast cancer and leukemia. Their work clears the way for the development of targeted drugs by refuting recent challenges to their approach.
A new study published in BMJ Oncology has found that relatively short-term use of immunosuppressant medications to control inflammatory diseases is not associated with an increased risk of developing cancer. The research included over 10,000 participants and tracked their cancer incidence for an average of 10 years.